Predictive factor and antihypertensive usage of tyrosine kinase inhibitor‑induced hypertension in kidney cancer patients

Izumi,Kouji; Itai,Shingo; Takahashi,Yoshiko; Maolake,Aerken; Namiki,Mikio

doi:10.3892/ol.2014.2060

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor‑induced hypertension in kidney cancer patients

Authors:
- Kouji Izumi
- Shingo Itai
- Yoshiko Takahashi
- Aerken Maolake
- Mikio Namiki
View Affiliations

Affiliations: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920‑8641, Japan, Department of Medicinal Informatics, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920‑8641, Japan
Published online on: April 11, 2014 https://doi.org/10.3892/ol.2014.2060
Pages: 305-308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor‑tyrosine kinase inhibitors (VEGFR‑TKI). The present study was performed to identify the predictive factors of TKI‑induced HT and to determine the classes of antihypertensive agents (AHTA) that demonstrate optimal efficacy against this type of HT. The charts of 50 cases of patients that had received VEGFR‑TKI treatment were retrospectively examined. The association between patient background and TKI‑induced HT, and the effect of administering AHTA were analyzed. High systolic blood pressure at baseline was identified to be a predictive factor for HT. In addition, there was no difference observed between calcium channel blockers (CCBs) and angiotensin receptor II blockers (ARBs) as first‑line AHTA for the control of HT. The findings of the present study may aid with predicting the onset of TKI‑induced HT, as well as for its management via the primary use of either CCBs or ARBs.

View Figures

View References

1	No authors listed. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 353:14–17. 1999.
2	Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 21:3127–3132. 2003.
3	McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 23:133–141. 2005.
4	Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 28:2137–2143. 2010.
5	Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 27:3312–3318. 2009.
6	Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009.
7	Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 378:1931–1939. 2011.
8	Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 28:1061–1068. 2010.
9	Horsley L, Marti K and Jayson GC: Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol. 8:283–293. 2012.
10	National Cancer Institute. Common Terminology Criteria for Adverse Events v.3.0 and v.4.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm. Accessed March 14, 2014
11	Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, et al; Japan Axitinib Phase II Study Group. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer. 47:2592–2602. 2011.
12	Goodwin R, Ding K, Seymour L, LeMaître A, Arnold A, Shepherd FA, et al; NCIC Clinical Trials Group. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol. 21:2220–2226. 2010.
13	Zhu X, Stergiopoulos K and Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 48:9–17. 2009.
14	Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, et al: Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol. 19:202–208. 2012.
15	Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 102:596–604. 2010.
16	Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al: Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 20:807–815. 2009.
17	Miyajima A, Kikuchi E, Kosaka T and Oya M: Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer. Rev Recent Clin Trials. 4:75–78. 2009.
18	Mc Menamin ÚC, Murray LJ, Cantwell MM and Hughes CM: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 23:221–230. 2012.
19	Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 363:2022–2031. 2004.
20	Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:1004–1010. 2002.